Menu Search
Equities

Henry Schein Inc

HSIC:NSQ

Henry Schein Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)76.89
  • Today's Change1.81 / 2.41%
  • Shares traded2.61m
  • 1 Year change+10.36%
  • Beta0.8636
Data delayed at least 15 minutes, as of Nov 25 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Henry Schein Inc's net income fell -22.68% from 538.00m to 416.00m despite relatively flat revenues. A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 21.91% to 23.78%.
Gross margin31.59%
Net profit margin2.42%
Operating margin4.04%
Return on assets2.97%
Return on equity8.78%
Return on investment4.86%
More ▼

Cash flow in USDView more

In 2023, Henry Schein Inc increased its cash reserves by 46.15%, or 54.00m. Cash Flow from Financing totalled 701.00m or 5.68% of revenues. In addition the company generated 500.00m in cash from operations while cash used for investing totalled 1.14bn.
Cash flow per share4.59
Price/Cash flow per share15.81
Book value per share27.99
Tangible book value per share-12.65
More ▼

Balance sheet in USDView more

Henry Schein Inc has a Debt to Total Capital ratio of 34.80%, a lower figure than the previous year's 49.71%.
Current ratio1.42
Quick ratio0.817
Total debt/total equity0.7574
Total debt/total capital0.348
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items dropped -19.15%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
EPS growth(5 years)2.98
EPS (TTM) vs
TTM 1 year ago		-27.32
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.